Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30311109 | 0.85 | DRD3 (0.34) | MEN1KMT2ADDB1CRBN | |
| SCHEMBL25947319 | 0.78 | MEN1 (0.46) | MEN1KMT2AAOC3GRM5 | |
| SCHEMBL31034869 | 0.77 | MEN1 (0.54) | MEN1KMT2AAOC3GRM5DDB1 | |
| SCHEMBL25308853 | 0.77 | MEN1 (0.54) | MEN1KMT2AAOC3GRM5DDB1 | |
| SCHEMBL30875685 | 0.75 | MEN1 (0.77) | MEN1KMT2AAOC3GRM5 | |
| SCHEMBL24869723 | 0.75 | MEN1 (0.77) | MEN1KMT2AAOC3GRM5 | |
| SCHEMBL21939251 | 0.74 | MEN1 (0.54) | MEN1KMT2AAOC3GRM5DDB1 | |
| SCHEMBL22981715 | 0.73 | MEN1 (0.49) | MEN1KMT2AGRM5DDB1CRBN | |
| SCHEMBL12489174 | 0.73 | GRM5 (0.52) | MEN1KMT2AAOC3GRM5 | |
| SCHEMBL29405544 | 0.73 | MEN1 (0.49) | MEN1KMT2AGRM5DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MEN1 2549/4885KMT2A 2987/4885AOC3 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.